Literature DB >> 7622804

Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis.

W Boyer1.   

Abstract

The etiology and optimum treatment of panic disorder remain unclear. Imipramine and alprazolam are reasonably well established treatments. Several reports have suggested that serotonin reuptake inhibitors may also be effective for this condition. To investigate this issue, 27 published or presented placebo-controlled, double-blind studies of DSM-III or DSM-III-R panic disorder were subjected to meta-analysis. The serotonin reuptake inhibitors included paroxetine, fluvoxamine, zimelidine, and clomipramine. The standard treatments were imipramine or alprazolam. All three treatments were highly significantly superior to placebo in alleviating panic. The serotonin reuptake inhibitors were also significantly superior to both imipramine and alprazolam. The superiority of the serotonin reuptake inhibitors remained, but was less pronounced, when they were compared to the studies which used higher doses of imipramine or alprazolam. These findings underscore the importance of serotonin reuptake inhibitors in the treatment of panic disorder and indirectly add to the evidence that serotonergic abnormalities may have a role in its etiology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622804     DOI: 10.1097/00004850-199503000-00006

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  14 in total

Review 1.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 2.  Panic disorder.

Authors:  M H Rapaport; C Barrett
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

Review 3.  Optimal management of anxiety in older patients.

Authors:  K J Weiss
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

4.  Screening antidepressants in the chick separation-stress paradigm.

Authors:  Matthew W Feltenstein; Kenneth J Sufka
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

5.  Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial.

Authors:  E Leinonen; U Lepola; H Koponen; J Turtonen; A Wade; H Lehto
Journal:  J Psychiatry Neurosci       Date:  2000-01       Impact factor: 6.186

6.  Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder.

Authors:  Sandeep Gyawali; Ryan Subaran; Myrna M Weissman; Dylan Hershkowitz; Morgan C McKenna; Ardesheer Talati; Abby J Fyer; Priya Wickramaratne; Phillip B Adams; Susan E Hodge; Carl J Schmidt; Michael J Bannon; Charles E Glatt
Journal:  Biol Psychiatry       Date:  2009-12-06       Impact factor: 13.382

Review 7.  Panic disorder.

Authors:  Shailesh Kumar; Darren Malone
Journal:  BMJ Clin Evid       Date:  2008-12-16

8.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

10.  Psychiatric treatment received by primary care patients with panic disorder with and without agoraphobia.

Authors:  Brook A Marcks; Risa B Weisberg; Martin B Keller
Journal:  Psychiatr Serv       Date:  2009-06       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.